Good
Mostly Aligned
Patient Risk:
Low
Summary
Most high-level identification and mechanism/indication statements align with the provided label context for CASODEX (bicalutamide), but the AI response does not specify the label-required 50 mg daily + LHRH analog combination and does not reflect the label’s restriction regarding CASODEX 150 mg not being approved. Brand/generic availability statements are not addressed in the provided label excerpts and are therefore unsupported.
Category Scores
Accurate Statements
Casodex (bicalutamide) is an anti-androgen medicine.
Label mechanism: CASODEX is a non-steroidal androgen receptor inhibitor (12.1).
Casodex (bicalutamide) is used in the treatment of prostate cancer.
Indication: Stage D2 metastatic carcinoma of the prostate in combination therapy with an LHRH analog (1).
Casodex (bicalutamide) is used for advanced prostate cancer.
Indication describes Stage D2 metastatic carcinoma of the prostate (1) (i.e., advanced/metastatic context within label).
Unsupported Statements
Bicalutamide is commonly sold under the brand name Casodex.
The provided prescribing information excerpts do not address brand-market prevalence or the statement that it is 'commonly sold' under that name.
Casodex is the main widely known brand name for bicalutamide.
The provided prescribing information excerpts do not address relative brand prominence or marketing familiarity.
Other bicalutamide products may exist by country.
The provided prescribing information excerpts do not address availability of other products by country.
Bicalutamide is available as a generic medicine in many markets.
The provided prescribing information excerpts do not address generic availability.
Contradictions
Important Omissions
Approved indication is specifically CASODEX 50 mg daily in combination with an LHRH analog for Stage D2 metastatic prostate cancer; the AI claims 'used in the treatment of prostate cancer' without stating the required combination/50 mg daily specificity.
Importance:
Moderate
The AI did not mention that CASODEX 150 mg daily is not approved for use alone or with other treatments.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The response contains no dosing instructions, contraindications, warnings, or interaction/monitoring guidance. The main label alignment gap is the omission of the approved 50 mg daily + LHRH analog combination specificity, which could affect accuracy but does not itself provide unsafe dosing directions.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Indication statements are too general and omit the label-required combination with an LHRH analog and the specific 50 mg daily dosing context; 150 mg not-approved statement is omitted.
Suggested Improvement
State that CASODEX is indicated as 50 mg once daily in combination with an LHRH analog for Stage D2 metastatic prostate cancer, and avoid adding brand/generic market claims not covered by the prescribing information excerpts.